Dr. Denise Faustman Continues Working Toward the Cure

Aug 5, 2008

Editor’s Note: In May 2005, we published an in-depth article discussing the brouhaha that erupted when the New York Times wrote about the JRDF’s unwillingness to fund Dr. Faustman’s ongoing research. Two medical doctors in the diabetes community and scientific colleagues of Faustman at Harvard Medical School wrote an enraged response to the Times article. After investigating both sides of the story, the Times declined to print the two doctors’ letter. The JDRF decided to take matters into its own hands and circulated an e-mail containing the unpublished doctors’ letter to JDRF chapters around the country.

Merrill Goozner, director of the Integrity in Science Project for The Center for Science in the Public Interest was disturbed to see the JDRF go to such great lengths to discredit Faustman. “It is shocking to see that scientists, rather than evaluating something on its merits, would spend so much time attacking the messenger,” he said. “You have to wonder, what is their real motivation? You would think that scientists connected with the JDRF would be pursuing every effective cure, not attacking approaches that rival their own.”

Diabetes Health is pleased to see that the Iacocca Foundation supports Dr. Faustman’s research and that she has made the exciting leap to human trials.

“Our goal is to reverse established type 1 diabetes, not simply temporarily halt it or treat its symptoms,” says Dr. Faustman. “If we can introduce this inexpensive drug to the market, it will be a tremendous achievement.”

After it saved the lives of diabetic mice, a drug used to treat tuberculosis and cancer is now being tested in humans at Massachusetts General Hospital as a possible cure for type 1 diabetes.

Denise Faustman, MD, PhD, director of the MGH Immunobiology Laboratory and associate professor of Medicine at Harvard Medical School, proved that the drug, Bacillus Calmette-Guérin (BCG), cured mice with end-stage diabetes in 2001. She is now leading a Phase I clinical trial in patients that began in February and is expected to take 18 months to complete. BCG is a generic drug with an excellent safety profile in humans. It causes the body to make a natural substance called TNF, which helps regulate the immune system by killing the rogue T-cells that cause diabetes.

BCG has been used safely for nearly 80 years as a tuberculosis vaccine. It is being used in the human trial because it causes a low-grade inflammatory reaction, which in the mouse model of autoimmune diabetes led to the destruction of the abnormal autoimmune cells.

David M. Nathan, MD, director of the MGH Diabetes Center, commented on the study, "This is the very first step in what is likely to be a long process in achieving a cure. We first need to determine whether the abnormal autoimmune cells that underlie type 1 diabetes can be knocked out with BCG vaccination, as occurred in the mouse studies." Trial information is available to the public at www.faustmanlab.org.

Dr. Faustman’s research is unique because most diabetes research focuses on new treatments involving blood glucose monitoring devices. There is almost no emphasis on disease reversal or cure. “Our goal is to reverse established type 1 diabetes, not simply temporarily halt it or treat its symptoms,” says Dr. Faustman. “If we can introduce this inexpensive drug to the market, it will be a tremendous achievement.”

The clinical trial is being supported largely through direct and fundraising support from the Iacocca Foundation and through support from other donors and the Massachusetts General Hospital. The Iacocca Foundation was founded by Lee Iacocca and his family in 1984 to fund innovative approaches to a potential cure for diabetes.

The launch of the clinical trial received press coverage in the U.S. and the U.K. For more information on the MGH Immunobiology Laboratory, go to http://www.faustmanlab.org.

Categories: Blood Glucose, Diabetes, Research, Type 1 Issues

You May Also Be Interested In...

Click Here To View Or Post Comments

Aug 5, 2008

Your Name:	Your Email:	X

Recipient's Name:	Recipient's Email:

Email to a Friend

Dr. Denise Faustman Continues Working Toward the Cure

You May Also Be Interested In...

Click Here To View Or Post Comments

Diabetes Health

Topics

Topics

Topics

Diabetes Health Medical Disclaimer